HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of ischemia-reperfusion and pretreatment with mildronate on rat liver mitochondrial function.

Abstract
Mildronate (3-(2,2,2-trimethylhydrazinium) propionate), which is mostly used in cardiological practice and is considered an anti-ischemic drug, was designed to inhibit carnitine biosynthesis in order to prevent accumulation of cytotoxic intermediate products of fatty acid beta-oxidation. Recently it was shown that the mitochondrial respiratory chain may also be a target for mildronate action. In this study, we aimed to investigate whether mildronate can protect the liver against a 90-min normothermic ischemia/30-min reperfusion-induced mitochondrial dysfunction. Rats were pre-treated for one or two weeks with mildronate (100 mg/kg/day or 200 mg/kg/day) or Ringer solution and subjected to ischemia/reperfusion.We found that ischemia/reperfusion caused a decrease in mitochondrial State 3 respiration rate and in the respiratory control index (RCI), and an increase in State 2 respiration rate with succinate, glutamate + malate and palmitoyl-L-carnitine + malate. One or two weeks of pre-treatment of rats with different doses of mildronate did not reduce the ischemia/reperfusion-induced decrease in the State 3 respiration rate or RCI; however, a one week pre-treatment slightly diminished the increase in the State 2 respiration rate with glutamate + malate substrates. The leakage of the liver enzymes, aspartate aminotransferase, alanine aminotransferase and lactate dehydrogenase, was similar in both the untreated and pre-treated with mildronate groups. No steatotic livers were observed in any experimental groups after mildronate pre-treatment. In conclusion, 90 min of liver ischemia followed by a 30 min reperfusion has a deleterious effect on rat liver mitochondrial function. Mildronate pre-treatment of rats at doses of 100 or 200 mg/kg/day for one or two weeks did not prevent ischemia/reperfusion-induced mitochondrial dysfunction and liver injury.
AuthorsSonata Trumbeckaite, Marius Kincius, Andrius Preidis, Monika Preidiene, Vincentas Veikutis, Vilmante Borutaite, Antanas Gulbinas
JournalPharmacological reports : PR (Pharmacol Rep) 2009 Sep-Oct Vol. 61 Issue 5 Pg. 859-69 ISSN: 2299-5684 [Electronic] Switzerland
PMID19904009 (Publication Type: Journal Article)
Chemical References
  • Cardiovascular Agents
  • Methylhydrazines
  • 3-(2,2,2-trimethylhydrazine)propionate
Topics
  • Animals
  • Cardiovascular Agents (administration & dosage, pharmacology)
  • Dose-Response Relationship, Drug
  • Female
  • Liver (drug effects, enzymology, pathology)
  • Liver Function Tests
  • Methylhydrazines (administration & dosage, pharmacology)
  • Mitochondria, Liver (drug effects, metabolism, pathology)
  • Rats
  • Rats, Wistar
  • Reperfusion Injury (physiopathology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: